CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765)
China
· Delayed Price · Currency is CNY 27.11
-0.47 (-1.70%)
Nov 13, 2024, 3:04 PM CST
CSPC Innovation Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 513.13 | 755.56 | 726.28 | 393.23 | 299.84 | 273.2 | Upgrade
|
| Depreciation & Amortization | 100.01 | 100.01 | 72.94 | 69.15 | 53.42 | 47.14 | Upgrade
|
| Other Amortization | 0.08 | 0.08 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.82 | 1.82 | 4.61 | - | 0.43 | -0.22 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 13.19 | - | 1.62 | Upgrade
|
| Loss (Gain) From Sale of Investments | -12.58 | -12.58 | -16.82 | -21.31 | -27.37 | -21.81 | Upgrade
|
| Provision & Write-off of Bad Debts | -4.85 | -4.85 | 7.8 | 6.03 | -1.41 | - | Upgrade
|
| Other Operating Activities | -731.54 | -25.39 | -54.64 | 9.16 | 2 | 1.83 | Upgrade
|
| Change in Accounts Receivable | 165.85 | 165.85 | -224.89 | -119.21 | 38.91 | -15.67 | Upgrade
|
| Change in Inventory | 3.9 | 3.9 | -24.82 | -113.85 | 13.23 | 5.21 | Upgrade
|
| Change in Accounts Payable | -58.65 | -58.65 | 157.24 | 56.71 | -32.27 | 24.78 | Upgrade
|
| Operating Cash Flow | -21.34 | 927.24 | 640.72 | 292.09 | 349.07 | 315.38 | Upgrade
|
| Operating Cash Flow Growth | - | 44.72% | 119.36% | -16.32% | 10.68% | 97.45% | Upgrade
|
| Capital Expenditures | -63.97 | -95.73 | -114.05 | -195.41 | -117.74 | -106.1 | Upgrade
|
| Sale of Property, Plant & Equipment | -1.15 | 3.75 | 5.82 | 2.3 | 2.84 | 0.42 | Upgrade
|
| Divestitures | - | - | - | 118.79 | - | - | Upgrade
|
| Investment in Securities | -436.88 | -1 | 416.52 | -88.46 | 435.95 | -968.05 | Upgrade
|
| Other Investing Activities | - | - | 3.59 | 7.43 | 25.12 | - | Upgrade
|
| Investing Cash Flow | -502 | -92.99 | 311.88 | -155.36 | 346.17 | -1,074 | Upgrade
|
| Long-Term Debt Issued | - | - | 20 | - | - | - | Upgrade
|
| Total Debt Issued | -0.2 | - | 20 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -70.16 | Upgrade
|
| Long-Term Debt Repaid | - | -20.86 | -0.86 | -0.86 | - | - | Upgrade
|
| Total Debt Repaid | -0.64 | -20.86 | -0.86 | -0.86 | - | -70.16 | Upgrade
|
| Net Debt Issued (Repaid) | -0.84 | -20.86 | 19.14 | -0.86 | - | -70.16 | Upgrade
|
| Issuance of Common Stock | - | 488.8 | - | - | - | 1,146 | Upgrade
|
| Repurchase of Common Stock | -1,420 | -4.25 | -0.07 | - | - | - | Upgrade
|
| Common Dividends Paid | -374.01 | -97.85 | -82.07 | -42 | -28 | - | Upgrade
|
| Other Financing Activities | -316.9 | -0.63 | - | - | - | -1.5 | Upgrade
|
| Financing Cash Flow | -2,112 | 365.21 | -63.01 | -42.86 | -28 | 1,075 | Upgrade
|
| Foreign Exchange Rate Adjustments | 21.18 | 31.17 | 57.55 | -6.88 | -2.13 | 2.27 | Upgrade
|
| Net Cash Flow | -2,614 | 1,231 | 947.14 | 86.98 | 665.11 | 318.74 | Upgrade
|
| Free Cash Flow | -85.31 | 831.51 | 526.67 | 96.67 | 231.33 | 209.28 | Upgrade
|
| Free Cash Flow Growth | - | 57.88% | 444.80% | -58.21% | 10.53% | 107.70% | Upgrade
|
| Free Cash Flow Margin | -4.17% | 33.24% | 20.05% | 5.23% | 17.56% | 16.66% | Upgrade
|
| Free Cash Flow Per Share | -0.06 | 0.60 | 0.39 | 0.07 | 0.20 | 0.19 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 1.5 | Upgrade
|
| Cash Income Tax Paid | 193.43 | 171.78 | 93.04 | 108.71 | 132.48 | 126.94 | Upgrade
|
| Levered Free Cash Flow | 594.96 | 612.74 | 434.79 | -59.54 | 33.68 | 243.42 | Upgrade
|
| Unlevered Free Cash Flow | 594.96 | 612.97 | 434.92 | -57.76 | 33.68 | 244.35 | Upgrade
|
| Change in Net Working Capital | -224.25 | -124.69 | -9.07 | 203.31 | 117.09 | -124.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.